{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:55Z","timestamp":1753891615999,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>An abnormal increase of \u03b1-synuclein in the brain is the hallmark of dementia with Lewy bodies (DLB). However, the diagnostic power of plasma \u03b1-synuclein in DLB is not yet confirmed. Parkinsonism is highly associated with and is one of the core clinical features of DLB. We studied plasma \u03b1-synuclein and developed a novel tool that combined plasma \u03b1-synuclein level and Motor Dysfunction Questionnaire (MDQ), namely Synuclein Motor Dysfunction Composite Scale (SMDCS), for the clinical discrimination of DLB from Alzheimer\u2019s disease (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cross-sectional study analyzed participants\u2019 demographical data, plasma \u03b1-synuclein level, MDQ, structured clinical history questionnaire, neuropsychological and motor function tests, and neuroimaging studies. The power of plasma \u03b1-synuclein level, MDQ, and SMDCS for discriminating DLB from non-demented controls (NC) or AD were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 121 participants diagnosed as 58 DLB, 31 AD, and 31 NC were enrolled. Patients with DLB had significantly higher mean plasma \u03b1-synuclein level (0.24 \u00b1 0.32 pg\/ml) compared to the NC group (0.08 \u00b1 0.05 pg\/ml) and the AD group (0.08 \u00b1 0.05 pg\/ml). The DLB group demonstrated higher MDQ (2.95 \u00b1 1.60) compared to the NC (0.42 \u00b1 0.98) or AD (0.44 \u00b1 0.99) groups. The sensitivity\/specificity of plasma \u03b1-synuclein level, MDQ, and SMDCS for differentiating DLB from non-DLB were 0.80\/0.64, 0.83\/0.89, and 0.88\/0.93, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both plasma \u03b1-synuclein and MDQ were significantly higher in patients with DLB compared to the NC or AD groups. The novel SMDCS, significantly improved accuracy for the clinical differentiation of DLB from AD or NC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.920591","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:49:24Z","timestamp":1652964564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer\u2019s Disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying-Tsung","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Orimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Uei","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shieh-Yueh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pai-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1600-0404.1997.tb00299.x","article-title":"The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with lewy bodies.","volume":"96","author":"Ballard","year":"1997","journal-title":"Acta. Neurol. Scand."},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood.","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00065","article-title":"Freezing of speech single questionnaire as a screening tool for cognitive dysfunction in patients with dementia with lewy bodies.","volume":"12","author":"Chiu","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.709215","article-title":"Motor dysfunction questionnaire and dopamine transporter imaging composite scale improve differentiating dementia with lewy bodies from alzheimer\u2019s Disease with motor dysfunction.","volume":"13","author":"Chiu","year":"2021","journal-title":"Front. Aging. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","article-title":"The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20535","article-title":"How to diagnose dementia with Lewy bodies: state of the art.","volume":"20","author":"Geser","year":"2005","journal-title":"Mov. Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in parkinson\u2019s disease with dementia and dementia with lewy bodies compared to alzheimer:s Disease.","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/437025","article-title":"alpha-Synuclein as CSF and Blood biomarker of dementia with lewy bodies.","volume":"2012","author":"Kasuga","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","article-title":"Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and alzheimer\u2019s Disease.","volume":"81","author":"Kasuga","year":"2010","journal-title":"J. Neurol. Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000329763","article-title":"Decreased alpha-synuclein serum levels in patients with lewy body dementia compared to alzheimer\u2019s Disease patients and control subjects.","volume":"31","author":"Laske","year":"2011","journal-title":"Dement Geriatr. Cogn. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living.","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson\u2019s disease.","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson\u2019s disease.","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000510325","article-title":"Plasma total alpha-synuclein and neurofilament light chain: clinical validation for discriminating Parkinson\u2019s Disease from normal control.","volume":"49","author":"Lin","year":"2020","journal-title":"Dement Geriatr. Cogn. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB Consortium.","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to alzheimer\u2019s Disease: recommendations from the national institute on aging-alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s Disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules.","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment.","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.055","article-title":"CSF alpha-synuclein levels in dementia with lewy bodies and alzheimer\u2019s Disease.","volume":"1251","author":"Noguchi-Shinohara","year":"2009","journal-title":"Brain Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"Ohrfelt","year":"2009","journal-title":"Neurosci. Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-2009-0955","article-title":"Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.","volume":"16","author":"Spies","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nicl.2017.09.009","article-title":"Biomarkers in Parkinson\u2019s Disease","author":"Surguchov","year":"2022","journal-title":"Neurodegenerative Diseases Biomarkers. Neuromethods"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1017\/s1041610294001602","article-title":"The cognitive abilities screening instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia.","volume":"6","author":"Teng","year":"1994","journal-title":"Int. Psychogeriatr."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00044","article-title":"An informant-based simple questionnaire for visuospatial dysfunction assessment in dementia.","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1109\/JTEHM.2019.2959331","article-title":"Analyze informant-based questionnaire for the early diagnosis of senile dementia using deep learning.","volume":"8","author":"Zhu","year":"2020","journal-title":"IEEE J. Transl. Eng. Health Med."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.11r01190","article-title":"Dementia with lewy bodies: diagnosis and management for primary care providers.","volume":"13","author":"Zupancic","year":"2011","journal-title":"Prim. Care Com. CNS Dis."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.920591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:49:26Z","timestamp":1652964566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.920591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":26,"alternative-id":["10.3389\/fnagi.2022.920591"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.920591","relation":{},"ISSN":["1663-4365"],"issn-type":[{"type":"electronic","value":"1663-4365"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"920591"}}